Ex­clu­sive: Strug­gling Ed­i­tas shops pre­clin­i­cal can­cer pipeline dur­ing its big makeover

Sto­ried CRISPR gene edit­ing pi­o­neer Ed­i­tas Med­i­cine $ED­IT is in ad­vanced dis­cus­sions re­gard­ing the sale of the pre­clin­i­cal on­col­o­gy line­up in its pipeline as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER